Astellas Pharma is appealing directly to the stockholder of CV Therapeutics, offering to give them $16 a share, an offer it has unsuccessfully made twice before to CV’s board, most recently a week ago.
“While we continue to prefer to reach a negotiated agreement Read the rest of this entry »
At the same time as it was apparently fending off uninvited takeover talk from Fremont-based Virage Logic, the board of directors at LogicVision of San Jose was fashioning new change-in-control agreements for its three top executives that helped insure bigger payouts for them.
Virage Logic sent a letter yesterday to LogicVision’s board in which it said it was “sincerely disappointed in your unwillingness to engage in any substantive discussions regarding our indication of interest transmitted to you on November 10th regarding an all-cash acquisition of LogicVision.” The proposal was to pay $1.05 per share for LogicVision, a 114 percent premium to its closing price the day before the letter was sent.
In his letter to LogicVision’s board, Read the rest of this entry »
In a letter that began “Dear Wally”, Cadence Design Chief Executive Michael Fister explained to Walden Rhines, his counterpart at Mentor Graphics, why he was forced to go public with their offer to buy Mentor two months after the wooing began, so far to no avail. Read the rest of this entry »
Subscribe via RSS all feeds - Tech feed - O'Brien feed - Docu-Drama feed - Pink Slip 2.0 feed
